Cellectis

OverviewSuggest Edit

The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

TypePublic
Founded1999
HQParis, FR
Websitecellectis.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Apr 2022)272
Job Openings13
Revenue (FY, 2020)$73.9 M(+387%)
Share Price (May 2022)€3(+2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cellectis

Andre Choulika

Andre Choulika

Chief Executive Officer and Board Director
Carrie Brownstein

Carrie Brownstein

Chief Medical Officer
Leopold Bertea

Leopold Bertea

Senior Vice President of Technical Operations - Europe
Philippe Duchateau

Philippe Duchateau

Chief Scientific Officer
Eric Dutang

Eric Dutang

Chief Financial Officer
Steve Doares

Steve Doares

Senior Vice President, US Manufacturing and Site Head
Show more

Cellectis Office Locations

Cellectis has offices in Paris, Lyon, New York and Raleigh
Paris, FR (HQ)
8 Rue de la Croix Jarry
Lyon, FR
28 Rue Laennec
New York, NY, US
430 E 29th St
Raleigh, NC, US
2500 Sumner Blvd
Show all (4)

Cellectis Financials and Metrics

Cellectis Revenue

Cellectis's revenue was reported to be $73.95 m in FY, 2020
USD

Revenue (Q3, 2021)

8.3m

Gross profit (Q3, 2021)

2.6m

Net income (Q3, 2021)

(40.1m)

EBITDA (Q3, 2021)

(38.5m)

EBIT (Q3, 2021)

(42.4m)

Market capitalization (13-May-2022)

135.2m

Closing stock price (13-May-2022)

3.0

Cash (30-Sept-2021)

210.7m

EV

29.1m
Cellectis's current market capitalization is €135.2 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

12.7m15.2m73.9m

Cost of goods sold

(11.9m)(13.8m)(39.7m)

Gross profit

9.6m9.2m42.7m

R&D expense

(42.0m)(57.1m)(49.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

1.0m1.2m8.6m50.1m2.9m7.0m25.6m11.2m8.3m

Cost of goods sold

(4.3m)(25.2m)(17.9m)(6.9m)(6.4m)(7.9m)(7.3m)(11.6m)(8.3m)

Gross profit

(839.0k)(22.3m)(7.6m)45.1m(1.8m)2.1m20.7m3.5m2.6m

R&D expense

(8.8m)5.4m(969.0k)(11.6m)(13.7m)(12.4m)(17.9m)(18.2m)(20.8m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

451.5m340.5m241.1m

Accounts Receivable

3.0m3.0m5.2m

Prepaid Expenses

15.1m15.5m24.8m

Inventories

275.0k2.9m1.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

421.5m397.0m342.5m287.1m260.7m260.9m207.5m248.2m210.7m

Accounts Receivable

2.8m3.0m8.0m3.0m4.0m4.0m6.4m3.9m348.0k

Prepaid Expenses

33.3m37.0m2.2m23.9m20.3m25.7m25.8m21.2m20.4m

Inventories

1.1m986.0k3.3m3.6m5.7m6.3m5.3m2.5m1.7m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(88.3m)(115.2m)(97.5m)

Depreciation and Amortization

2.4m6.9m9.8m

Inventories

(37.0k)(2.6m)1.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(17.7m)(54.5m)(73.9m)16.6m(19.3m)(52.0m)(15.3m)(57.0m)(97.0m)

Depreciation and Amortization

1.5m3.2m4.9m2.1m4.2m6.8m3.8m7.2m11.5m

Inventories

(788.0k)(709.0k)(3.1m)(702.0k)(2.8m)(3.4m)(3.7m)(866.0k)(74.0k)

Accounts Payable

2.4m4.0m3.8m
Show all financial metrics

Cellectis Revenue Breakdown

Embed Graph

Cellectis revenue breakdown by business segment: 69.0% from THERAPEUTIQUE and 31.0% from PLANTES

Cellectis Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Cellectis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Cellectis Online and Social Media Presence

Embed Graph

Cellectis News and Updates

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

◦   UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the publication of two manuscripts in Nature C…

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces today that its partner Cytovia Therapeutics, …

Thinking about buying stock in Excellon Resources, Cellectis, Superior Drilling Products, Safe T Group, or Drive Shack?

NEW YORK, March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXN, CLLS, SDPI, SFET, and DS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported business objectives for its products pipeline and in-house manuf…

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

NEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop innovative therapeutics for the treatment of serious diseases, announced today preliminary results …
Show more

Cellectis Blogs

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its combined general meeting on June 28, 20…

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

New York, NY – May 16, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research data on the development of a novel …

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN Received a $20 million convertible note un…

Cellectis to Report First Quarter 2022 Financial Results

New York, NY – May 5, 2022 – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarte…

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

New York, NY – May 5, 2022 – Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology com…

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cells Preclinical data shows proof-of-principle that UCART123 cells have potent anti-BPDCN activity Human evaluation of UCART123 is currently in Phase 1 clinical tria…
Show more

Cellectis Frequently Asked Questions

  • When was Cellectis founded?

    Cellectis was founded in 1999.

  • Who are Cellectis key executives?

    Cellectis's key executives are Andre Choulika, Carrie Brownstein and Leopold Bertea.

  • How many employees does Cellectis have?

    Cellectis has 272 employees.

  • What is Cellectis revenue?

    Latest Cellectis annual revenue is $73.9 m.

  • What is Cellectis revenue per employee?

    Latest Cellectis revenue per employee is $271.9 k.

  • Who are Cellectis competitors?

    Competitors of Cellectis include Polymun, Allogene Therapeutics and EMS Pharma.

  • Where is Cellectis headquarters?

    Cellectis headquarters is located at 8 Rue de la Croix Jarry, Paris.

  • Where are Cellectis offices?

    Cellectis has offices in Paris, Lyon, New York and Raleigh.

  • How many offices does Cellectis have?

    Cellectis has 4 offices.